Our findings suggest that TGFBR3 overexpression is a potential approach for clinical treatment of NPC, provided that TGFBR3 gene therapy could be applied to the right types of NPC with the right cellular context to produce the right consequence with minimal ‘off-target’ effects. The gene discussed is TGFBR3; the disease is nasopharyngeal carcinoma.